Octasa: Octasa

Octasa: Octasa

This paper will show how, despite a tiny budget, a me-too product, an uninterested audience and only 11 sales reps, Octasa successfully relaunched its branded drug for the treatment of ulcerative colitis (UC), a conditon which leads to inflammation of the colon and the rectum. It demonstrates that communications activity turned a three-year investment of 1.2 million into cumulative across three years sales of 20.3 million, achieving a revenue payback of 16.41 for every 1 invested.